Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study

• Sponsor: AstraZeneca (Industry)
• Overall Status: Completed
• CT.gov ID: NCT00228514
• Collaborator: (none)
• Enrollment: 40
• Location: 1
• Duration (Months): 40.9
• Patients Per Site Per Month: 1

Study Details

Study Description

Brief Summary

At one site, patients participating in the Corona main study are asked to participate in the PET-substudy. Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed to study the effect of rosuvastatin in Chronic Heart Failure on myocardial perfusion (reserve)

Condition or Disease	Intervention/Treatment	Phase
Rosuvastatin; Heart Failure; Positron Emission Tomography (PET)	Drug: Rosuvastatin; Procedure: Positron emission tomography	Phase 3

Study Design

• Study Type: Interventional
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double
• Primary Purpose: Treatment
• Official Title: Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) PET Sub Study
• Study Start Date: Feb 1, 2004
• Actual Study Completion Date: Jul 1, 2007

Outcome Measures

Primary Outcome Measures

1. To study the effect of rosuvastatin in Chronic Heart Failure on myocardial perfusion (reserve). Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed. []

Secondary Outcome Measures

1. To study the effect of rosuvastatin in Chronic Heart Failure on mismatch. Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed. []

Eligibility Criteria

Criteria

• Ages Eligible for Study: 60 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients fulfilling the in and exclusion criteria of the CORONA study and separate informed consent for participation in the sub study.

Exclusion Criteria:

• See above

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Research Site	Groningen		Netherlands

Sponsors and Collaborators

• AstraZeneca

Investigators

• Study Director: AstraZeneca CV Medical Department, AstraZeneca BV

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00228514
• Other Study ID Numbers: 4522IL/0098 Dutch SubStudy; D3562C00098
• First Posted: Sep 29, 2005
• Last Update Posted: Nov 15, 2010
• Last Verified: Nov 1, 2010

• Additional relevant MeSH terms: Heart Failure; Rosuvastatin Calcium

Study Results

No Results Posted as of Nov 15, 2010